You are here: Industry Insights > Symtuza

News List

Janssen's Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis pharmafile
April 23, 2019
Janssen's Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis
Encouraging data for ViiV’s long-acting, two-drug HIV therapy pharmatimes
November 01, 2018
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV...
Janssen unveils long-term data for HIV drug Symtuza pharmatimes
November 01, 2018
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV...
FDA Approves Symtuza americanpharmaceuticalreview
July 24, 2018
The U.S. Food and Drug Administration (FDA) has approved Janssen's Symtuza, the first and only complete, darunavir-based single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically su
Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in the market fiercepharma
July 23, 2018
Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition.
US approves Janssen’s HIV pill Symtuza pharmatimes
July 19, 2018
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
Janssen receives EMA committee recommendation to market Symtuza for HIV pharmaceutical-technology
July 27, 2017
Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Symtuza for the treatment of HIV.